Apomorphine-induced myocardial protection is due to antioxidant and not adrenergic/dopaminergic effects

Free Radical Biology and Medicine

Volumn 40, Issue 10, 2006, Pages 1713-1720

  Khaliulin, Igor ^a   Schneider, Aviva ^a   Houminer, Esther ^a   Borman, Joseph B ^a   Schwalb, Herzl ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Carbonyls; Free radicals; Haloperidol; Heart; Ischemia; l DOPA; Propranolol

Indexed keywords

APOMORPHINE; PROPRANOLOL;

ADRENERGIC ACTIVITY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARBONYLATION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFECT; HEART FUNCTION; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

ANIMALIA;

EID: 33646135066     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.01.001     Document Type: Article

References (53)

1. Di Chiara G., and Gessa G.L. Pharmacology and neurochemistry of apomorphine. Adv. Pharmacol. Chemother. 15 (1978) 87-160
2. Gassen M., Glinka Y., Pinchasi B., and Youdim M.B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308 (1996) 219-225
3. Gassen M., Gross A., and Youdim M.B. Apomorphine, a dopamine receptor agonist with remarkable antioxidant and cytoprotective properties. Adv. Neurol. 80 (1999) 297-302
4. Khaliulin I., Borman J.B., Chevion M., and Schwalb H. Cardioprotective and antioxidant effects of apomorphine. Free Radic. Res. 37 (2003) 721-730
5. Gancher S.T., Woodward W.R., Boucher B., and Nutt J.G. Peripheral pharmacokinetics of apomorphine in humans. Ann. Neurol. 26 (1989) 232-238
6. Spencer J.P., Jenner A., Butler J., Aruoma O.I., Dexter D.T., Jenner P., and Halliwell B. Evaluation of the pro-oxidant and antioxidant actions of l-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic. Res. 24 (1996) 95-105
7. Le W.D., and Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease?. Drugs Aging 18 (2001) 389-396
8. Youdim M.B., Gassen M., Gross A., Mandel S., and Grunblatt E. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. J. Neural Transm. Suppl.: (2000) 83-96
9. 3H]dopamine in the ventricles of guinea-pig heart are of DA2 type. Pharmacol. Res. Commun. 18 (1986) 1151-1157
10. Emilien G., Maloteaux J.M., Geurts M., Hoogenberg K., and Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol. Ther. 84 (1999) 133-156
11. Smit A.J. Dopamine and the kidney. Neth. J. Med. 34 (1989) 47-58
12. Cross H.R., Steenbergen C., Lefkowitz R.J., Koch W.J., and Murphy E. Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ. Res. 85 (1999) 1077-1084
13. Schomig A., and Richardt G. Cardiac sympathetic activity in myocardial ischemia: release and effects of noradrenaline. Basic Res. Cardiol. 85 Suppl. 1 (1990) 9-30
14. Lubbe W.F., Podzuweit T., and Opie L.H. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J. Am. Coll. Cardiol. 19 (1992) 1622-1633
15. Carlsson L. Mechanisms of local noradrenaline release in acute myocardial ischemia. Acta Physiol. Scand. Suppl. 559 (1987) 1-85
16. Stamm C., Friehs I., Cowan D.B., Cao-Danh H., Choi Y.H., Duebener L.F., McGowan F.X., and del Nido P.J. Dopamine treatment of postischemic contractile dysfunction rapidly induces calcium-dependent pro-apoptotic signaling. Circulation 106 (2002) I290-I298
17. Billman G.E. The antiarrhythmic and antifibrillatory effects of calcium antagonists. J. Cardiovasc. Pharmacol. 18 Suppl. 10 (1991) S107-S117
18. Khaliulin I., Schneider A., Houminer E., Borman J.B., and Schwalb H. Apomorphine prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart. Free Radic. Biol. Med. 37 (2004) 969-976
19. Neely J.R., and Rovetto M.J. Techniques for perfusing isolated rat hearts. Methods Enzymol. 39 (1975) 43-60
20. Shacter E. Protein oxidative damage. Methods Enzymol. 319 (2000) 428-436
21. Goldberg L.I. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol. Rev. 24 (1972) 1-29
22. Rousseau M.F., Raigoso J., van Eyll C., Van Mechelen H., Musso N.R., Lotti G., and Pouleur H. Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure. J. Cardiovasc. Pharmacol. 19 (1992) 155-162
23. Takamatsu I., Karasawa F., and Okuda T. Dopamine may preserve the myocardial oxygen balance better than dobutamine when administered with milrinone. Can. J. Anaesth. 49 (2002) 968-972
24. Gassen M., and Youdim M.B. Free radical scavengers: chemical concepts and clinical relevance. J. Neural Transm. Suppl. 56 (1999) 193-210
25. Teisman A.C., van Veldhuisen D.J., Scholtens E., Maselbas W., and van Gilst W.H. Effects of selective dopaminergic receptor stimulation on ventricular remodeling after experimental myocardial infarction in rats. J. Card. Fail. 3 (1997) 199-205
26. Goldstein M., Freedman L.S., and Backstrom T. The inhibition of catecholamine biosynthesis by apomorphine. J. Pharm. Pharmacol. 22 (1970) 715-717
27. Bigornia L., Allen C.N., Jan C.R., Lyon R.A., Titeler M., and Schneider A.S. D2 dopamine receptors modulate calcium channel currents and catecholamine secretion in bovine adrenal chromaffin cells. J. Pharmacol. Exp. Ther. 252 (1990) 586-592
28. Hietala J. Effects of DA-1-and DA-2-dopamine antagonists on apomorphine-induced inhibition of peripheral sympathetic neurotransmission. J. Auton. Pharmacol. 8 (1988) 297-302
29. Smit A.J., and Girbes A.R. Dopamine agonists in heart failure: an untimely death. Neth. J. Med. 51 (1997) 151-153
30. Brodde O.E., O'Hara N., Zerkowski H.R., and Rohm N. Human cardiac beta-adrenoceptors: both beta 1- and beta 2-adrenoceptors are functionally coupled to the adenylate cyclase in right atrium. J. Cardiovasc. Pharmacol. 6 (1984) 1184-1191
31. Lokhandwala M.F., and Hegde S.S. Cardiovascular pharmacology of adrenergic and dopaminergic receptors: therapeutic significance in congestive heart failure. Am. J. Med. 90 (1991) 2S-9S
32. Schapira A.H. Neuroprotection in PD-A role for dopamine agonists?. Neurology 61 (2003) S34-S42
33. Youdim M.B., Gassen M., Gross A., Mandel S., and Grunblatt E. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. J. Neural Transm. Suppl.: (2000) 83-96
34. Ubeda A., Montesinos C., Paya M., and Alcaraz M.J. Iron-reducing and free-radical-scavenging properties of apomorphine and some related benzylisoquinolines. Free Radic. Biol. Med. 15 (1993) 159-167
35. Berenshtein E., Mayer B., Goldberg C., Kitrossky N., and Chevion M. Patterns of mobilization of copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J. Mol. Cell. Cardiol. 29 (1997) 3025-3034
36. Hermida-Ameijeiras A., Mendez-Alvarez E., Sanchez-Iglesias S., Sanmartin-Suarez C., and Soto-Otero R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem. Int. 45 (2004) 103-116
37. Smith T.S., Parker Jr. W.D., and Bennett Jr. J.P. l-DOPA increases nigral production of hydroxyl radicals in vivo: potential l-DOPA toxicity?. Neuroreport 5 (1994) 1009-1011
38. Grunblatt E., Mandel S., Berkuzki T., and Youdim M.B. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14 (1999) 612-618
39. Youdim M.B., Grunblatt E., and Mandel S. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration: prospects for neuroprotection in Parkinson's disease with iron chelators. Ann. N.Y. Acad. Sci. 890 (1999) 7-25
40. Picada J.N., Maris A.F., Ckless K., Salvador M., Khromov-Borisov N.N., and Henriques J.A. Differential mutagenic, antimutagenic and cytotoxic responses induced by apomorphine and its oxidation product, 8-oxo-apomorphine-semiquinone, in bacteria and yeast. Mutat. Res. 539 (2003) 29-41
41. Kyriazis M. Neuroprotective, anti-apoptotic effects of apomorphine. J. Anti Aging Med. 6 (2003) 21-28
42. Chen Y.K., Lin H.C., Liu J.C., and Wan F.J. Potent, hydroxyl radical-scavenging effect of apomorphine with iron and dopamine perfusion in rat striatum. Brain Res. 896 (2001) 165-168
43. Habuchi Y., Tanaka H., Yamamoto T., Komori T., Nishio M., and Yoshimura M. The mechanisms underlying heart stimulation by dopamine, with special reference to direct and indirect beta adrenoceptor stimulation. Clin. Exp. Hypertens. 19 (1997) 141-154
44. Hoque A.N., Nasa Y., and Abiko Y. Cardioprotective effect of d-propranolol in ischemic-reperfused isolated rat hearts. Eur. J. Pharmacol. 236 (1993) 269-277
45. Jin X.Z., and Liu G.D. Prevention of postischemic reperfusion damage on isolated working rat hearts by bopindolol and propranolol. Zhongguo Yaoli Xuebao 10 (1989) 394-398
46. Freedman A.M., Kramer J.H., Mak I.T., Cassidy M.M., and Weglicki W.B. Propranolol preserves ultrastructure in adult cardiocytes exposed to anoxia/reoxygenation: a morphometric analysis. Free Radic. Biol. Med. 11 (1991) 197-206
47. Kramer J.H., Mak I.T., Freedman A.M., and Weglicki W.B. Propranolol reduces anoxia/reoxygenation-mediated injury of adult myocytes through an anti-radical mechanism. J. Mol. Cell. Cardiol. 23 (1991) 1231-1244
48. Polster B.M., Basanez G., Young M., Suzuki M., and Fiskum G. Inhibition of Bax-induced cytochrome c release from neural cell and brain mitochondria by dibucaine and propranolol. J. Neurosci. 23 (2003) 2735-2743
49. Frances C., Nazeyrollas P., Prevost A., Moreau F., Pisani J., Davani S., Kantelip J.P., and Millart H. Role of beta 1- and beta 2-adrenoceptor subtypes in preconditioning against myocardial dysfunction after ischemia and reperfusion. J. Cardiovasc. Pharmacol. 41 (2003) 396-405
50. Powell S.R., Gurzenda E.M., and Wahezi S.E. Actin is oxidized during myocardial ischemia. Free Radic. Biol. Med. 30 (2001) 1171-1176
51. Dalle-Donne I., Rossi R., Giustarini D., Milzani A., and Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta 329 (2003) 23-38
52. Mehvar R., and Brocks D.R. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J. Pharm. Pharm. Sci. 4 (2001) 185-200
53. Imamura Y., Wu X., Noda A., and Noda H. Side-chain metabolism of propranolol: involvement of monoamine oxidase and mitochondrial aldehyde dehydrogenase in the metabolism of N-desisopropylpropranolol to naphthoxylactic acid in rat liver. Life Sci. 70 (2002) 2687-2697